Skip to main content
VIMGF logo

Vimian Group AB (publ) (VIMGF) Stock Price & Analysis

Vimian Group AB (publ) (VIMGF) — price $4.16 (0.00%), as of the Nov 19, 2026 trading session; market cap $2.20B.

Educational signal · not a buy or sell recommendation · How to read this

$4.16 $0.00 (0.00%) Market Cap $2.20B

Vimian Group AB (publ) · VIMGF

Vimian Group AB (publ) operates in the animal health sector, offering a range of products and services across diagnostics, pharmaceuticals, MedTech, and veterinary services. The company focuses on preventive care and chronic condition treatments for companion animals and livestock.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • IDXX · IDEXX Laboratories, Inc. · 96 /100
  • ZTS · Zoetis Inc. · 87 /100
  • NEOG · Neogen Corporation · 34 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$4.16
Change on the day0.00%
52-week range$2.68 – $4.16
Market capitalisation$2.20B—
Price / earnings (trailing)50.82
Shares traded on the day7.0K

Price & events

1 · What is it?

What is Vimian Group AB (publ) (VIMGF), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Vimian Group AB (publ) (VIMGF) is the company analyzed here. It employs 1,300 people and is led by Alireza Tajbakhsh. In Q3 FY2026 it reported revenue of €115M and net income of €8M. The market values it at $2.20B.

2 · Latest results

What do the latest results show for Vimian Group AB (publ) (VIMGF)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of €115M. Against analyst estimates the company has EPS beat 1 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026€115M€8M€0.02 (diluted)
Q2 FY2026€119M€8M€0.02 (diluted)
Q1 FY2026€116M€10M€0.02 (diluted)
Q4 FY2025€109M€12M€0.02 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Vimian Group AB (publ) (VIMGF)?

Short answer · as of

The distress and quality screens read Altman Z 3.70 · Piotroski F 6. Trailing ratios: ROE 5.4% · ROA 3.3% · current ratio 2.73 · earnings yield 1.9% · free-cash-flow yield 4.5%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held VIMGF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported VIMGF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Vimian Group AB (publ) Stock: Key Questions Answered

These answers are editorial: 1 of these 8 answers is drawn from the VIMGF research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is VIMGF a good stock to buy?

Stock Expert AI does not rate VIMGF buy, sell or hold. Vimian Group AB (publ) has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the VIMGF stock price today?

The last price recorded for Vimian Group AB (publ) (VIMGF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for VIMGF?

Vimian Group faces several risks inherent to the animal health industry. Intense competition from established players like Zoetis and IDEXX Laboratories could impact market share and pricing power.

What are the key factors to evaluate for VIMGF?

Evaluate VIMGF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Development of Advanced Diagnostics: Vimian's Indical Bioscience is focused on developing advanced molecular and immunodiagnostic solutions for veterinary laboratories. Not financial advice.

How frequently does VIMGF data refresh on this page?

VIMGF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven VIMGF's recent stock price performance?

Vimian Group AB (publ) (VIMGF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified business model across multiple segments of the animal health market. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider VIMGF overvalued or undervalued right now?

The trailing P/E of Vimian Group AB (publ) (VIMGF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research VIMGF before investing?

Before investing in Vimian Group AB (publ) (VIMGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 15 figures on this page — 8 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.